HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA

Publish Date: 
Tuesday, September 27, 2016

We know that very early treatment in acute HIV infection decreases HIV RNA; this study shows it also greatly decreases proviral DNA (and reservoir size). Researchers investigated 2 small cohorts of patients in Thailand with acute (and very early) HIV infection, 1 untreated and 1 treated with ART very early; patients were followed for 144 weeks. They found that DNA integration occurs early and rapidly, and that with early and continued ART, total and integrated HIV DNA drops quickly and continues to decrease over time.

HIV Meds Update: Improvements in ART and Viral Suppression Rates in the United States

Publish Date: 
Tuesday, September 27, 2016

Using data from the Medical Monitoring Project, this article presents a useful view of ARV treatment in the United States. The analysis demonstrates that U.S. national rates of both ARV prescribing (for persons maintained in care) and viral suppression to <200 copies/mL increased from 2009 to 2013--last at 94% and 80%, respectively, with notable increases over time in nearly all demographic subgroups examined, including women, younger-aged patients, and non-Hispanic blacks. Not surprisingly, though, disparities in viral suppression remain.

HIV Meds Update: HIV in Indiana

Publish Date: 
Monday, September 26, 2016

This article describes the CDC investigation and response (through October 2015) to the ongoing HIV (and HCV) outbreak in a rural county in Indiana, centered in people who inject opiates (especially the prescription drug Opana [oxymorphone]). The outbreak was first recognized in 2015 and continues to spiral onward--there are now >200 cases.

HIV and Heart Disease – NIH Explores the Connection

Publish Date: 
Wednesday, June 15, 2016

HIV-positive men and women can now live longer than ever before. A 2013 study found that a newly diagnosed 20-year-old on effective antiretroviral therapy (ART) can expect to live into their 70s, a lifespan only slightly lower than in people without HIV.[1] While this is great news, physicians are learning that chronic HIV infection can place their patients at a higher risk of developing certain health problems earlier in life. One example is heart disease.

PrEP: Bone Density Improves after Stopping TDF/FTC

Publish Date: 
Wednesday, May 4, 2016

Tenofovir disoproxil fumarate (TDF) may cause decreases in bone mineral density (BMD) both in HIV-infected patients treated with TDF-containing ARV regimens and in HIV-uninfected persons who use it for PrEP.

TAF/FTC Coformulation Approved

Publish Date: 
Thursday, April 28, 2016
The FDA has approved a new 2-NRTI formulation containing tenofovir alafenamide (TAF) 25 mg + emtricitabine (FTC) 200 mg for adults and children ≥12 years of age; its brand name is Descovy.

Accessibility: The Bigger Picture

Publish Date: 
Thursday, June 2, 2016

selection from infographic. 74.8 million adults in the U.S. have at least one disibility or mobility limitation.I have been working on website accessibility for many years in my role as Production Manager at the UCSF Center for HIV Information. Despite that experience, I still encounter problems that confound me. I recently reached out to an accessibility expert for ideas on how to manage a particularly difficult compliance problem.

Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy

Publish Date: 
Tuesday, April 12, 2016

Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted darunavir during pregnancy.


Subscribe to Sharespot RSS feed